



Mixson, J.A.
Continuation Under 1.53(b) of S.N. 09/500,838

REMARKS

Claims 1-20 are replaced before action with claims 21-35, drawn to RNA embodiments.

The specification is amended to insert the citation to the journal reference into the correct location.

A PTO 1449 is submitted with this application.

If any additional fee is required by this submission, please charge account no. 03-2775.

Date: _____

11/29/01

Respectfully submitted,

By: _____

Robert G. McMorrow, Jr.
Reg. No. 30,962
CONNOLLY BOVE LODGE & HUTZ LLP
1220 Market Street
P. O. Box 2207
Wilmington, DE 19899
(302) 658-9141

Attorneys for Applicant

10036869-112901



APPENDIX 1

A marked up copy of the amended paragraph spanning pages 18-19 is shown below, with additions underlined and deleted text in brackets.

The plasmid vector may contain multiple promoters to enhance expression efficiency. Moreover, a plasmid vector may include IRES sequence (internal ribosome entry site) between different DNA coding sequences, allowing for the translation of more than one peptide from the same transcript. Coding sequences can be associated with secretory sequences in the vector to enhance expression levels. In another embodiment of the invention, the vector may comprise an extrachromosomal replicating vector. See, e.g. Calos, TIG 12:463 (1996). In a further embodiment, RNA carries the coding sequence of antiangiogenic genes. [See, e.g. Calos, TIG 12:463 (1996).] These and other techniques to optimize expression are known to those in the art.

10036869.12901